RESTON, Va., Oct. 24, 2018 /PRNewswire/ — Leidos (NYSE: LDOS) Chairman and Chief Executive Officer Roger Krone today attended the signing of the “Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act” or SUPPORT for Patients and Communities Act at the White House, committing his support with other private industry executives to help end the opioid epidemic.

More than 200 people attended the event, including members of Congress, and leaders from 20 other participating companies. Krone was accompanied by John Hindman, who helped initiate the Leidos efforts in this area nearly two years ago.

“Even though I lost a child, I know I’m not alone,” said Hindman. “Today’s event is more than symbolism, it represents the sincere actions of the government and organizations to address this epidemic that’s ravaging our very nation and even the world. I applaud them for taking concrete steps.”

Leidos is committed to its ongoing corporate responsibility efforts to help end the opioid epidemic and is furthering initiatives to educate the company’s workforce of 32,000 employees. It is also working to launch a coalition of companies to address the crisis through its CEO pledge. Already, Leidos has established relationships with organizations including the Truth Initiative, Community Anti-Drug Coalitions of America, the Chris Atwood Foundation, and the Mark Wahlberg Youth Foundation. The company has also worked with Deterra® to distribute safe disposal pouches in local communities.

“Our industry is fortunate to have responsible corporate citizens that are charged with taking care of our communities,” said Leidos Chairman and CEO Roger Krone. “I’m especially grateful to attend this event with John who challenged our company to increase community awareness about the dangers of substance abuse – we’re committed to continuing efforts that answer that call.”

About Leidos
Leidos is a Fortune 500^® information technology, engineering, and science solutions and services leader working to solve the world’s toughest challenges in the defense, intelligence, homeland security, civil, and health markets. The company’s 32,000 employees support vital missions for government and commercial customers. Headquartered in Reston, Virginia, Leidos reported annual revenues of approximately $10.17 billion for the fiscal year ended December 29, 2017. For more information, visit www.Leidos.com.

Statements in this announcement, other than historical data and information, constitute forward-looking statements that involve risks and uncertainties. A number of factors could cause our actual results, performance, achievements, or industry results to be very different from the results, performance, or achievements expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to, the risk factors set forth in the company’s Annual Report on Form 10-K for the period ended December 29, 2017, and other such filings that Leidos makes with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.

View original content to download multimedia:http://www.prnewswire.com/news-releases/leidos-chairman-and-ceo-joins-industry-leaders-at-signing-of-white-house-opioid-act-300737208.html

SOURCE Leidos